Company ·
Daewon Pharmaceutical holds a peptide molecule tracked on the Peptide Exchange board.
Daewon Pharmaceutical has 1 molecule on the board and 1 news move logged. Each card shows the molecule's class, mechanism and current stage; open it for the full stage history.
Holdings
Incretins
GLP 1 receptor agonist semaglutide in an in house polymer and lipid complex oral delivery platform
Daewon's oral semaglutide formulation showed 1.90 to 3.14 times the exposure of Rybelsus in two small crossover studies, the company says. A phase 1 filing in Korea is planned for 2027.
Log
Daewon Pharmaceutical reports total exposure 1.90 to 3.14 times that of Rybelsus in two crossover studies of 18 and 19 people. No safety or efficacy data were shared, and a formal phase 1 filing in Korea is planned for 2027.
Holds P1